首页 | 官方网站   微博 | 高级检索  
     


Application of the adverse outcome pathway framework to genotoxic modes of action
Authors:Jennifer C Sasaki  Ashley Allemang  Steven M Bryce  Laura Custer  Kerry L Dearfield  Yasmin Dietz  Azeddine Elhajouji  Patricia A Escobar  Albert J Fornace Jr  Roland Froetschl  Sheila Galloway  Ulrike Hemmann  Giel Hendriks  Heng-Hong Li  Mirjam Luijten  Gladys Ouedraogo  Lauren Peel  Stefan Pfuhler  Daniel J Roberts  Véronique Thybaud  Jan van Benthem  Carole L Yauk  Maik Schuler
Affiliation:1. Genentech, Inc., South San Francisco, California;2. Procter & Gamble, Mason, Ohio;3. Litron Laboratories, Rochester, New York;4. Bristol-Myers Squibb Company, Drug Safety Evaluation, New Brunswick, New Jersey;5. Burke, Virginia;6. Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany;7. Novartis Pharma AG, Basel, Switzerland;8. Merck &Co. Inc., West Point, Pennsylvania;9. Georgetown University, Washington, District of Columbia;10. Federal Institute for Drugs and Medical Devices, Bonn, Germany;11. Toxys, Leiden, The Netherlands;12. National Institute for Public Health and the Environment, Bilthoven, The Netherlands;13. L'oréal Recherche & Innovation, Aulnay-Sous-Bois, France;14. Health and Environmental Sciences Institute, Washington, District of Columbia;15. Charles River Laboratoires, Skokie, Illinois;16. Sanofi, Research and Development, Preclinical Safety, Vitry-sur-Seine, France;17. Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada;18. Pfizer Inc, World Wide Research and Development, Groton, Connecticut
Abstract:In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc.
Keywords:adverse outcome pathway  mode of action  genotoxicity
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号